Executive Summary

Oct 2019
PROSPECTS
Self-medication prevails as stigmatisation lingers

Most dermatologicals categories are related to sensitive issues, as people commonly associate the conditions and these products with low hygiene standards. As a result, dermatological issues may cause a lot of discomfort, as people are often reluctant to talk about them.

Rising health-awareness allows consumers to cut down on dermatologicals

The decline in growth rate in 2019 indicates that dermatologicals has approached maturity, as sales rises are set to keep decelerating over the forecast period. Maturity has resulted in increasing competition and a growing number of price-based promotions.

Internet consultation and sales can overcome the stigma of buying dermatologicals

The development of online pharmacies has helped to overcome stigmas related to dermatological conditions. People can easily access all information relating to the products and compare it with similar products in a faster and more convenient way online.

COMPETITIVE LANDSCAPE
Bayer leads the way

With the exception of GSK Consumer Healthcare, which jumped up the rankings thanks to absorbing the brands of Pfizer Inc and GlaxoSmithKline Plc, sales shares among the leading players in 2019 remained similar to those posted in 2019. As a result, Bayer, by being the dominant company in the large category of nappy (diaper) rash treatments with its Bepanthen brand, continued to lead dermatologicals in 2019.

A solid reputation for quality is key for brands

Brand-awareness and trust in quality remain the common core of the consumer decision-making process. Therefore, those companies offering well-recognised brands with good quality performed well over the review period, including in 2019.

Switches to OTC and online information investment could offer sales potential

Vaginal antifungals has witnessed the most significant change in recent years thanks to the launch of Canesten by Bayer OÜ. Due to the possibility of precisely measuring doses of clotrimazolum, Canesten was granted OTC status for the lower content of its active ingredient, while all other products with this ingredient remain Rx.

Want to find out more about this report?
Request more information
Why buy this report?

Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.

Your Recently Viewed Reports

Dermatologicals in Estonia

Samples (FAQs about samples):

Delivery: Files are delivered directly into your account within a few minutes of purchase.

Overview

Discover the latest market trends and uncover sources of future market growth for the Medicated Skin Care industry in Estonia with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Medicated Skin Care industry in Estonia, our research will save you time and money while empowering you to make informed, profitable decisions.

The Medicated Skin Care in Estonia market research report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volumes and values, company and brand market shares
  • Five year forecasts of market trends and market growth
  • Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

  • What is the market size of Medicated Skin Care in Estonia?
  • What are the major brands in Estonia?
  • What are the most popular formats for acne treatments?

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Dermatologicals in Estonia - Category analysis

HEADLINES

PROSPECTS

Self-medication prevails as stigmatisation lingers
Rising health-awareness allows consumers to cut down on dermatologicals
Internet consultation and sales can overcome the stigma of buying dermatologicals

COMPETITIVE LANDSCAPE

Bayer leads the way
A solid reputation for quality is key for brands
Switches to OTC and online information investment could offer sales potential

CATEGORY DATA

Table 1 Sales of Dermatologicals by Category: Value 2014-2019
Table 2 Sales of Dermatologicals by Category: % Value Growth 2014-2019
Table 3 NBO Company Shares of Dermatologicals: % Value 2015-2019
Table 4 LBN Brand Shares of Dermatologicals: % Value 2016-2019
Table 5 Forecast Sales of Dermatologicals by Category: Value 2019-2024
Table 6 Forecast Sales of Dermatologicals by Category: % Value Growth 2019-2024

Consumer Health in Estonia - Industry Overview

EXECUTIVE SUMMARY

Estonians’ interest in consumer health increases
Price-competition strengthens, while consumers’ rising health knowledge benefits smaller categories
Competitive landscape trends in 2019 are consumer-fuelled
Channels for non-OTC products are the more dynamic
A more moderate performance is predicted as maturity sets in

MARKET INDICATORS

Table 7 Consumer Expenditure on Health Goods and Medical Services: Value 2014-2019
Table 8 Life Expectancy at Birth 2014-2019

MARKET DATA

Table 9 Sales of Consumer Health by Category: Value 2014-2019
Table 10 Sales of Consumer Health by Category: % Value Growth 2014-2019
Table 11 NBO Company Shares of Consumer Health: % Value 2015-2019
Table 12 LBN Brand Shares of Consumer Health: % Value 2016-2019
Table 13 Distribution of Consumer Health by Format: % Value 2014-2019
Table 14 Distribution of Consumer Health by Format and Category: % Value 2019
Table 15 Forecast Sales of Consumer Health by Category: Value 2019-2024
Table 16 Forecast Sales of Consumer Health by Category: % Value Growth 2019-2024

APPENDIX

OTC registration and classification
Vitamins and dietary supplements registration and classification
Self-medication/self-care and preventive medicine
Switches

DEFINITIONS

SOURCES

Summary 1 Research Sources